Your browser doesn't support javascript.
Relating In Vitro Neutralization Level and Protection in the CVnCoV (CUREVAC) Trial.
Cromer, Deborah; Reynaldi, Arnold; Steain, Megan; Triccas, James A; Davenport, Miles P; Khoury, David S.
  • Cromer D; Kirby Institute, University of New South Wales, Sydney, Australia.
  • Reynaldi A; Kirby Institute, University of New South Wales, Sydney, Australia.
  • Steain M; School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
  • Triccas JA; Sydney Institute of Infectious Diseases and Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia.
  • Davenport MP; School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
  • Khoury DS; Sydney Institute of Infectious Diseases and Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia.
Clin Infect Dis ; 75(1): e878-e879, 2022 Aug 24.
Article in English | MEDLINE | ID: covidwho-1769230
ABSTRACT
The vaccine candidate CVnCoV (CUREVAC) showed surprisingly low efficacy in a recent phase 3 trial compared with other messenger RNA (mRNA) vaccines. Here we show that the low efficacy follows from the dose used and the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and is predicted by the neutralizing antibody response induced by the vaccine.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / COVID-19 Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: Cid

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / COVID-19 Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: Cid